GlassScriptPhysician profile
Rebecca Turk
NPI 1861466856
$501.03
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $144 · 2021: $37.07 · 2022: $48.06.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $119.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $66.39 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $51.40 | 2019 | |
| Sanofi Pasteur INC. | $39.46 | 2019-2020 | |
| Kaleo, INC. | $37.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.73 | 2019-2020 | |
| Neos Therapeutics, LP | $30.10 | 2019 | |
| Cranial Technologies, INC | $28.07 | 2019 | |
| Corium, LLC | $23.82 | 2021 | |
| Genentech USA, INC. | $23.44 | 2020 | |
| Supernus Pharmaceuticals, INC. | $18.21 | 2022 | |
| Adlon Therapeutics L.P. | $17.46 | 2019 | |
| Seqirus USA INC | $14.18 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Turk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.